MALT1 and glioblastoma: MALT1 mRNA expression was the only gene product with a negative prognostic impact on OS in the GBM patients (HR (95% CI range) = 1.997 (1.1–3.625); p = 0.023) and, therefore, can be targeted for immune therapies.